12th December 2016
BBI Solutions launches a new enzyme for Urinalysis
BBI Solutions (BBI) has announced the launch of Porcine Liver Esterase (PLE), a new enzyme for Urinalysis.
BBI have been developing and manufacturing enzymes for over 60 years. PLE joins a comprehensive range of high quality enzymes developed in house by an experienced team of scientists.
PLE is used in Urinalysis controls as a partial substitute for Human Leukocyte Esterase and can provide a cost-effective alternative. It acts on water-soluble carboxyl esters containing short chain fatty acids.
Assay control manufacturers can use PLE to detect the presence of white blood cells and other abnormalities associated with an infection of the urinary tract.
Urinary tract infections (UTIs) are responsible for nearly 10 million doctor visits each year.¹ Therefore BBI’s PLE will be used in products that can help to correctly diagnose these patients, improving the ease of diagnosis for the physician as well as the patient.
“As an organisation it’s great to be able to bring another high quality product to the market,” explained Janeske Oosthuizen, BBI’s Enzymes Product Manager. “We always ensure our raw materials come from a secure source and through our validated manufacturing process we can guarantee a high quality product through batch to batch consistency, even in bulk quantities.”
This is BBI’s first Urinalysis enzyme and extends their product portfolio to cover an even wider range of controls.